Printer Friendly

AMERICAN BIOGENETIC SCIENCES FILES WITH THE FDA TO BEGIN CLINICAL TRIALS OF BLOOD CLOT DETECTION ANTIBODY

AMERICAN BIOGENETIC SCIENCES FILES WITH THE FDA TO BEGIN CLINICAL TRIALS
 OF BLOOD CLOT DETECTION ANTIBODY
 NOTRE DAME, Ind., March 9 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) announced today that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for approval to begin human trials with its proprietary monoclonal antibody MH-1 to image blood clots.
 Blood clots leading to heart attack and stroke are the leading cause of death in the developed world.
 Pre-clinical studies have demonstrated that MH-1, linked to technetium using ABS's proprietary direct labeling technology, can determine the size and location of blood clots in the lungs in as early as 5 minutes following injection. It is the first known antibody to image clots in the lungs and in the heart.
 Henry L. Nordhoff, ABS's president, commented, "Today's filing represents an important milestone for the company. We estimate that the potential worldwide market for blood clot imaging agents is over $1 billion annually. ABS is also developing MH-1 as an extremely rapid site-specific monoclonal antibody that can be used to deliver medication to dissolve clots. The market for this delivery system is estimated to be twice as large as the imaging agent market."
 American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research at the University of Notre Dame, and Trinity College Dublin, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease and the early diagnosis Alzheimer's disease. These antibodies are produced from the company's proprietary antigen- minimized mouse colony. The company is also developing a recombinant vaccine for Hepatitis A.
 -0- 3/9/92
 /CONTACT: Fran Giambanco, vice president-administration, of American Biogenetic Sciences, 516-789-2600, or Phil Fried of The Dilenschneider Group, 212-922-0900, or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic Sciences Inc. ST: Indiana IN: MTC SU: SH-TS -- NY016 -- 6252 03/09/92 09:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:324
Previous Article:BENGUET REPORTS EARNINGS FOR 1991
Next Article:INTRAMED LABORATORIES INC. FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING OF COMMON STOCK
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES FIBRIN ANTIBODY PATENT ALLOWED
ABS PREVIEWS CARDIOVASCULAR PRODUCTS
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES NEW PRESIDENT KENNETH H. BURK, PH.D.
DEACONESS HOSPITAL AND HARVARD MEDICAL SCHOOL REPORT SIGNIFICANT PROGRESS IN CLINICAL EVALUATION;
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES ITS COMPLETION OF PHASE I, INITIATION OF PHASE I II CLINICAL TRIAL OF MH1 FOR IMAGING BLOOD CLOTS
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES PRESENTATION OF THREE ABSTRACTS ON ITS SOLFIB ASSAY AT CONGRESS OF THE INTERNATIONAL SOCIETY ON...
AMERICAN BIOGENETIC SCIENCES ISSUED U.S. PATENT NO. 5,453,359 FOR THROMBUS PRECURSOR PROTEIN (TpP) (SOLUBLE FIBRIN POLYMER)
Renal Dialysis Joint Venture Announced by American Biogenetic Sciences, Inc. and Gull Laboratories, Inc.
American Biogenetic Sciences, Inc. Receives FDA Clearance for its Patented Thrombus Precursor Protein (TpP) Diagnostic Test

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters